Zerodol P is a combination of Aceclofenac and Paracetamol.
Aceclofenac is a non-steroidal anti-inflammatory drug (NSAID) with marked anti-inflammatory and analgesic properties. It potently inhibits the synthesis of inflammatory mediators that cause pain, swelling, inflammation, and fever. In osteoarthritis and other such conditions, the loss of articular cartilage in the area causes joint pain, tenderness, stiffness, crepitus, and local inflammation. Aceclofenac has high permeability to penetrate into synovial joints thereby reducing the swelling and inflammation of joints.
Paracetamol is an analgesic and antipyretic medication used for mild-to-moderate pain and fever. Hence, Zerodol P is prescibed in conditions like osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. It is also effective in other painful conditions such as dental and gynaecological conditions.
Zerodol P is brand from Ipca, a global pharmaceutical company. Ipca has been partnering healthcare globally in over 120 countries for more than 60 years and in markets as diverse as Africa, Asia, Australia, Europe and the US. It is a fully-integrated Indian pharmaceutical company manufacturing over 350 formulations. The formulations are produced right from the basic stage at manufacturing facilities inspected by the world’s most discerning drug regulatory authorities like US-FDA, UK-MHRA, EDQM-Europe, WHO-Geneva and many more.
Ipca is a therapy leader in India for anti-malarials and has leading brands in 5 therapeutic areas, with 3 of their branded formulations being ranked among the Top-300 Indian brands by ORG-IMS.